tiprankstipranks
Trending News
More News >
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269

Wuxi Biologics (Cayman) (2269) Revenue

Compare
40 Followers

Wuxi Biologics (Cayman) Revenue

Wuxi Biologics (Cayman) had a revenue of 8.57B in the quarter ending Jun 30, 2024, with 0.37%. This bring the company's revenue in the last twelve months to 17.12B, Decreased 0.48%. In the fiscal year ending Dec 31, 2024, Wuxi Biologics (Cayman) had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
17.12B
Revenue Growth
7.52%
P/S Ratio
5.26
Revenue/Employee
$1,485,119
Employees
12,575
Market Cap
$98.14B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
18.68B1.64B+9.63%
Dec 31, 2023
17.03B1.77B+11.56%
Dec 31, 2022
15.27B4.98B+48.38%
Dec 31, 2021
10.29B4.68B+83.35%
Dec 31, 2020
5.61B1.63B+40.88%
Dec 31, 2019
3.98B1.45B+57.18%
Dec 31, 2018
2.53B915.62M+56.56%
Dec 31, 2017
1.62B629.80M+63.68%
Dec 31, 2016
989.03M
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis